MATINAS BIOPHARMA HOLDINGS, INC. Equity Securities, FV-NI, Realized Loss
MATINAS BIOPHARMA HOLDINGS, INC. (MTNB) reported Equity Securities, FV-NI, Realized Loss of $0 for the 12-month period ending 2021-12-31, per its 10-K/A filed 2022-03-11.
Discontinued › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiRealizedLoss · last filed 2022-03-11
- MATINAS BIOPHARMA HOLDINGS, INC. equity securities, fv-ni, realized loss for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- MATINAS BIOPHARMA HOLDINGS, INC. equity securities, fv-ni, realized loss for fiscal 2020 was $9.00K.
| Period end | Equity Securities, FV-NI, Realized Loss 12 month |
|---|---|
| 2021-12-31 | $0.00 10-K/A · filed 2022-03-11 |
| 2020-12-31 | $9.00K 10-K/A · filed 2022-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B |